New drug duo targets tough lung cancer mutation
NCT ID NCT07164170
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a combination of two drugs, ABSK043 and glecirasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The study will enroll 86 participants to see if the combination is safe and can shrink tumors. It is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABSK043 combined with glecirasib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a specific genetic mutation in advanced lung cancer.
- What could go wrong
- This is an early-phase trial with only 86 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Central Hospital Affiliated to Shangdong First Medical University
NOT_YET_RECRUITINGJinan, Shangdong, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
-
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institude
NOT_YET_RECRUITINGNanning, Guangxi, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
Hunan Cancer Hospitial
RECRUITINGChangsha, Hunan, China
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Anhui Medical University
NOT_YET_RECRUITINGHefei, Anhui, China
-
The First Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi’an, Shanxi, China
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
-
Tongji Hospital Tongji Medical College of Hust
NOT_YET_RECRUITINGWuhan, Hubei, China
-
West China Hospital Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Zhongda Hospital Southeast University
RECRUITINGNanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?